{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:51:53Z","timestamp":1791395513644,"version":"4.3.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Foundation of Science Technology Department of Zhejiang Province","award":["LKLY25H160006"],"award-info":[{"award-number":["LKLY25H160006"]}]},{"name":"Foundation of Science Technology Department of Zhejiang Province","award":["LBY24H080001"],"award-info":[{"award-number":["LBY24H080001"]}]},{"name":"Foundation of Science Technology Department of Zhejiang Province","award":["LKLZ26H080001"],"award-info":[{"award-number":["LKLZ26H080001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470182"],"award-info":[{"award-number":["82470182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key R&D Program of Hangzhou Science and Technology Bureau","award":["2025SZD1B13"],"award-info":[{"award-number":["2025SZD1B13"]}]},{"name":"Construction Fund of Key Medical Disciplines of Hangzhou-Laboratory Diagnostics","award":["2025HZZD01"],"award-info":[{"award-number":["2025HZZD01"]}]},{"name":"Natural Science Foundation of Hangzhou","award":["2024SZRYBC080002"],"award-info":[{"award-number":["2024SZRYBC080002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04396-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:47:34Z","timestamp":1776779254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Hui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"4396_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5:341\u2013353. https:\/\/doi.org\/10.1016\/S1470-2045(04)01490-1","journal-title":"Lancet Oncol"},{"key":"4396_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.critrevonc.2016.10.005","volume":"107","author":"M Eskian","year":"2016","unstructured":"Eskian M, Khorasanizadeh M, Kraeber-Bodere F, Rezaei N (2016) Radioimmunotherapy in Non-Hodgkin lymphoma: prediction and assessment of response. Crit Rev Oncol Hematol 107:182\u2013189. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.10.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"4396_CR3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/CM9.0000000000002919","volume":"137","author":"W Zhang","year":"2024","unstructured":"Zhang W, Liu M, Li W, Song Y (2024) Immune cells in the b-cell lymphoma microenvironment: from basic research to clinical applications. Chin Med J (Engl) 137:776\u2013790. https:\/\/doi.org\/10.1097\/CM9.0000000000002919","journal-title":"Chin Med J (Engl)"},{"key":"4396_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00281-018-0696-7","volume":"41","author":"U Klausen","year":"2019","unstructured":"Klausen U, J\u00f8rgensen NGD, Grauslund JH et al (2019) Cancer immune therapy for lymphoid malignancies: recent advances. Semin Immunopathol 41:111\u2013124. https:\/\/doi.org\/10.1007\/s00281-018-0696-7","journal-title":"Semin Immunopathol"},{"key":"4396_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1142172","author":"W Yi-Ying","year":"2023","unstructured":"Yi-Ying W, Te-Kai S, Ming-Shan C et al (2023) Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2023.1142172","journal-title":"Front Cell Infect Microbiol"},{"key":"4396_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1172\/JCI24624","volume":"115","author":"HL Kaufman","year":"2005","unstructured":"Kaufman HL, Deraffele G, Mitcham J (2005) Targeting the local tumor microenvironment with Vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115:1903\u20131912. https:\/\/doi.org\/10.1172\/JCI24624","journal-title":"J Clin Invest"},{"key":"4396_CR7","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1128\/JVI.02561-08","volume":"83","author":"M Robinson","year":"2009","unstructured":"Robinson M, Li B, Ge Y et al (2009) Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J Virol 83:3450\u20133462. https:\/\/doi.org\/10.1128\/JVI.02561-08","journal-title":"J Virol"},{"key":"4396_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jcis.2024.05.175","volume":"671","author":"J Huang","year":"2024","unstructured":"Huang J, Ji L, Si J et al (2024) Platelet membrane-coated oncolytic Vaccinia virus with indocyanine green for the second near-infrared imaging guided multi-modal therapy of colorectal cancer. J Colloid Interface Sci 671:216\u2013231. https:\/\/doi.org\/10.1016\/j.jcis.2024.05.175","journal-title":"J Colloid Interface Sci"},{"key":"4396_CR9","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/microorganisms11071850","volume":"11","author":"X Han","year":"2023","unstructured":"Han X, Sun J, Lv X et al (2023) A recombinant oncolytic pseudorabies virus expressing interleukin-18, interferon-gamma and PH20 genes promotes systemic antitumor immunity. Microorganisms 11:1850. https:\/\/doi.org\/10.3390\/microorganisms11071850","journal-title":"Microorganisms"},{"key":"4396_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1615817","volume":"8","author":"M Moehler","year":"2019","unstructured":"Moehler M, Heo J, Lee HC et al (2019) Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after Sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 8:1615817. https:\/\/doi.org\/10.1080\/2162402X.2019.1615817","journal-title":"Oncoimmunology"},{"key":"4396_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166135","volume":"14","author":"JA Bluestone","year":"2023","unstructured":"Bluestone JA, McKenzie BS, Beilke J, Ramsdell F (2023) Opportunities for treg cell therapy for the treatment of human disease. Front Immunol 14:1166135. https:\/\/doi.org\/10.3389\/fimmu.2023.1166135","journal-title":"Front Immunol"},{"key":"4396_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","volume":"15","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann HM, Dwyer CJ, Bailey SR et al (2018) When worlds collide: Th17 and treg cells in cancer and autoimmunity. Cell Mol Immunol 15:458\u2013469. https:\/\/doi.org\/10.1038\/s41423-018-0004-4","journal-title":"Cell Mol Immunol"},{"key":"4396_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"JH Kang","year":"2023","unstructured":"Kang JH, Zappasodi R (2023) Modulating treg stability to improve cancer immunotherapy. Trends Cancer 9:911\u2013927. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.015","journal-title":"Trends Cancer"},{"key":"4396_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14728222.2018.1451514","volume":"22","author":"TL Whiteside","year":"2018","unstructured":"Whiteside TL (2018) FOXP3+ treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets 22:353\u2013363. https:\/\/doi.org\/10.1080\/14728222.2018.1451514","journal-title":"Expert Opin Ther Targets"},{"key":"4396_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Sakaguchi S (2019) Targeting treg cells in cancer immunotherapy. Eur J Immunol 49:1140\u20131146. https:\/\/doi.org\/10.1002\/eji.201847659","journal-title":"Eur J Immunol"},{"key":"4396_CR16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jtho.2025.02.029","volume":"20","author":"P Chen","year":"2025","unstructured":"Chen P, Wang H, Tang Z et al (2025) Selective depletion of CCR8+treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells. J Thorac Oncol 20:1050\u20131074. https:\/\/doi.org\/10.1016\/j.jtho.2025.02.029","journal-title":"J Thorac Oncol"},{"key":"4396_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat Rev Clin Oncol 16:356\u2013371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7","journal-title":"Nat Rev Clin Oncol"},{"key":"4396_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070865","volume":"16","author":"M-Y Li","year":"2024","unstructured":"Li M-Y, Ye W, Luo K-W (2024) Immunotherapies targeting tumor-associated macrophages (TAMs) in cancer. Pharmaceutics 16:865. https:\/\/doi.org\/10.3390\/pharmaceutics16070865","journal-title":"Pharmaceutics"},{"key":"4396_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115195","volume":"163","author":"X Liang","year":"2025","unstructured":"Liang X, Bai R, Sun Y et al (2025) TAMs: guardians or foes? Overcoming heterogeneity and delivery barriers for precision immunotherapy. Int Immunopharmacol 163:115195. https:\/\/doi.org\/10.1016\/j.intimp.2025.115195","journal-title":"Int Immunopharmacol"},{"key":"4396_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041295","volume":"15","author":"ME Davola","year":"2023","unstructured":"Davola ME, Cormier O, Vito A et al (2023) Oncolytic BHV-1 is sufficient to induce immunogenic cell death and synergizes with low-dose chemotherapy to dampen immunosuppressive T regulatory cells. Cancers Basel 15:1295. https:\/\/doi.org\/10.3390\/cancers15041295","journal-title":"Cancers Basel"},{"key":"4396_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009062","volume":"12","author":"K DePeaux","year":"2024","unstructured":"DePeaux K, Gunn WG, Rivadeneira DB, Delgoffe GM (2024) Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells. J Immunother Cancer 12:e009062. https:\/\/doi.org\/10.1136\/jitc-2024-009062","journal-title":"J Immunother Cancer"},{"key":"4396_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688\u2013696. https:\/\/doi.org\/10.1200\/JCO.1995.13.3.688","journal-title":"J Clin Oncol"},{"key":"4396_CR23","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA (2014) IL-2: the first effective immunotherapy for human cancer. J Immunol 192:5451\u20135458. https:\/\/doi.org\/10.4049\/jimmunol.1490019","journal-title":"J Immunol"},{"key":"4396_CR24","first-page":"1537","volume":"57","author":"S Jw","year":"1997","unstructured":"Jw S, Em J, Ce W et al (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537\u20131546","journal-title":"Cancer Res"},{"key":"4396_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028472","volume":"10","author":"TA Waldmann","year":"2018","unstructured":"Waldmann TA (2018) Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol 10:a028472. https:\/\/doi.org\/10.1101\/cshperspect.a028472","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4396_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120:6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y","journal-title":"Br J Cancer"},{"key":"4396_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0091-6749(99)70518-x","volume":"103","author":"CA Dinarello","year":"1999","unstructured":"Dinarello CA (1999) IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103:11\u201324. https:\/\/doi.org\/10.1016\/s0091-6749(99)70518-x","journal-title":"J Allergy Clin Immunol"},{"key":"4396_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919973","volume":"13","author":"SA Ihim","year":"2022","unstructured":"Ihim SA, Abubakar SD, Zian Z et al (2022) Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front Immunol 13:919973. https:\/\/doi.org\/10.3389\/fimmu.2022.919973","journal-title":"Front Immunol"},{"key":"4396_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024241","volume":"6","author":"BW-C Tse","year":"2011","unstructured":"Tse BW-C, Russell PJ, Lochner M et al (2011) IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS ONE 6:e24241. https:\/\/doi.org\/10.1371\/journal.pone.0024241","journal-title":"PLoS ONE"},{"key":"4396_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12616","author":"G K","year":"2018","unstructured":"K G (2018) Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. https:\/\/doi.org\/10.1111\/imr.12616","journal-title":"Immunol Rev"},{"key":"4396_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou T, Damsky W, Weizman O-E et al (2020) IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583:609\u2013614. https:\/\/doi.org\/10.1038\/s41586-020-2422-6","journal-title":"Nature"},{"key":"4396_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/cncr.24100","volume":"115","author":"AA Tarhini","year":"2009","unstructured":"Tarhini AA, Millward M, Mainwaring P et al (2009) A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115:859\u2013868. https:\/\/doi.org\/10.1002\/cncr.24100","journal-title":"Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04396-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:47:35Z","timestamp":1776779255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04396-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4396"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04396-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animals were supplied by the Laboratory Animal Center of Hangzhou Medical College (Hangzhou, China). Animals were maintained at 22\u201326\u00a0\u00b0C and at 45\u201365% humidity in a 12\u00a0h light\u2013dark cycle and given unlimited food and water. All the experimental procedures were carried out according to the Guide for the Care and Use of Laboratory Animals. (Approval Number: ZJCLA-IACUC-20011109).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors contributed to and have approved the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"150"}}